GPCR
Structure Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$47.34
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.2M | 3.9M | — | — | — |
| Gross Profit | (1.2M) | (3.9M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 294.4M | 225.3M | 108.8M | 70.1M | 36.2M |
| SG&A Expense | 73.8M | 61.6M | 49.4M | 32.7M | 16.4M |
| General & Admin Expense | 73.8M | 61.6M | 49.4M | 32.7M | 16.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (111.4M) | (3.1M) | — | — | — |
| Total Operating Expenses | 256.9M | 283.7M | 158.2M | 102.8M | 52.6M |
| Cost and Expenses | 258.1M | 287.6M | 158.2M | 102.8M | 52.6M |
| Operating Income (EBIT) | (258.1M) | (287.6M) | (158.2M) | (102.8M) | (52.6M) |
| Non-Operating | |||||
| Interest Income | 32.2M | 36.0M | 36.0M | 13.4M | 1.3M |
| Interest Expense | — | — | — | 13.4M | — |
| Net Interest Income | 32.2M | 36.0M | 36.0M | (11.6K) | 1.3M |
| Other Non-Op Income/Expense | 43.7M | 146.5M | 36.0M | 13.4M | 1.3M |
| Non-Operating Income (excl Interest) | (43.7M) | (146.9M) | (36.0M) | (26.8M) | (1.3M) |
| EBT (Pre-Tax Income) | (214.4M) | (140.7M) | (122.2M) | (89.4M) | (51.3M) |
| Income Tax Expense | 702.6K | 515.0K | 310.0K | 236.0K | 17.0K |
| Bottom Line | |||||
| Net Income | (215.1M) | (141.2M) | (122.5M) | (89.6M) | (51.3M) |
| Earnings from Cont. Ops | (215.1M) | (141.2M) | (122.5M) | (89.6M) | (51.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (215.1M) | (141.2M) | (122.5M) | (89.6M) | (52.8M) |
| Per Share | |||||
| Basic EPS | ($3.03) | ($2.40) | ($2.34) | ($2.43) | ($1.44) |
| Diluted EPS | ($3.03) | ($2.40) | ($2.34) | ($2.43) | ($1.44) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 72.7M | 59.2M | 52.6M | 36.7M | 36.6M |
| Diluted Shares Outstanding | 72.7M | 59.2M | 52.6M | 36.7M | 36.6M |
| Profitability Metrics | |||||
| EBITDA | (212.4M) | (136.8M) | (121.2M) | (75.7M) | (51.0M) |
| D&A | 1.9M | 3.9M | 992.0K | 295.0K | 277.0K |
| EBIT | (214.4M) | (140.7M) | (122.2M) | (76.0M) | (51.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026